Myasthenia gravis trials in China

In China 42 Also abroad 123

42 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis
Where
Beijing, Chengdu, Chongqing, Nanchang, Suzhou
Age
18 years and over
People
120 worldwide
Run by
UCB Biopharma SRL
See details and how to joinNCT07463521 · EU 2025-524756-54-00
Phase 3Taking people
A Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis
Where
Beijing, Chongqing, Nanchang, Suzhou
Age
18 years and over
People
100 worldwide
Run by
UCB Biopharma SRL
See details and how to joinNCT07465289 · EU 2025-524757-14-00
Phase 3Taking people
A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
Where
Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Jinan, Shanghai, Tianjin, Xi'an
Age
18 years and over
People
199 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT04951622 · EU 2023-504152-97-00
Early phase 1Not yet taking people in China
A Clinical Study to Evaluate the Safety and Efficacy of GT802 Injection in the Treatment of Refractory Generalized Myasthenia Gravis
Where
Wuhan
Age
18 years to 65 years
People
12
Run by
Daishi Tian
See details and how to joinNCT07917923
Phase 2Taking people
A Phase II Study of SHR-2173 Injection in Patients With Myasthenia Gravis
Where
Changsha, Shanghai
Age
18 years to 75 years
People
60
Run by
Guangdong Hengrui Pharmaceutical Co., Ltd
See details and how to joinNCT07622342
Phase 3Taking people
Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
Where
Anhui Sheng, Beijing, Changchun, Changsha, Chengdu, Guangzhou, Shanghai, Shenyang, Shijiazhuang, Wuhan, Xi'an, Zhengzhou, Zunyi
Age
18 years and over
People
264 worldwide
Run by
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
See details and how to joinNCT06463587 · EU 2023-507746-83-00
Phase 3Taking people
Efficacy and Safety of Ravulizumab in Chinese Adults Participants With Generalized Myasthenia Gravis (gMG)
Where
Beijing, Changchun, Fuzhou, Jinan, Shanghai, Shijiazhuang, Taiyuan, Tianjin, Wuhan, Zhengzhou
Age
18 years to 130 years
People
20
Run by
Alexion Pharmaceuticals, Inc.
See details and how to joinNCT07596784
Phase 1/2Taking people
Safety and Efficacy of BAFF-R CART for Refractory Neuroimmune Diseases
Where
Tianjin
Age
18 years to 60 years
People
27
Run by
Tianjin Medical University General Hospital
See details and how to joinNCT07022197
Phase 1Not yet taking people in China
An Open-label, Dose-escalation Phase Ib Study of EA5 Injection in Adults With Anti-AChR Antibody-Positive Generalized Myasthenia Gravis
Where
Beijing, Shanghai
Age
18 years and over
People
18
Run by
Shanghai Lanyi Therapeutics Co., Ltd.
See details and how to joinNCT07818291
Phase 1Taking people
Clinical Study of Cizutamig in Generalized Myasthenia Gravis (gMG)
Where
Changchun, Chengdu, Fuzhou, Guangzhou, Guiyang, Shanghai, Taiyuan, Tianjin, Zhengzhou
Age
18 years and over
People
44
Run by
Candid Therapeutics
See details and how to joinNCT07215650
Phase 2/3Taking people
A Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis.
Where
Beijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Jinan, Kunming, Nanchang, Qingdao, Shanghai, Shenzhen, Wuhan, Xi'an, Zunyi
Age
18 years to 70 years
People
104
Run by
Shanghai Jiaolian Drug Research and Development Co., Ltd
See details and how to joinNCT06447597
Phase 1Taking people
A Study to Evaluate the Safety and Preliminary Efficacy of SYS6020 CAR T-cells in Patients With Refractory Generalized Myasthenia Gravis
Where
Jinan
Age
18 years to 65 years
People
60
Run by
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
See details and how to joinNCT06688435
Phase 1Not yet taking people in China
Efficacy and Safety of HN2301 in Patients With Generalized Myasthenia Gravis (MG)
Where
Hefei
Age
18 years to 80 years
People
6
Run by
Shenzhen MagicRNA Biotechnology Co., Ltd
See details and how to joinNCT07556120
No phaseTaking people
Biomarkers in Autoimmune Disease of Nervous System
Where
Wuhan
Age
18 years and over
People
50,000
Run by
Tongji Hospital
See details and how to joinNCT06502015
Phase 1Not yet taking people in China
Universal STAR-T Cell Injection in Generalized Myasthenia Gravis
Where
Wuhan
Age
18 years to 65 years
People
10
Run by
Daishi Tian
See details and how to joinNCT07714798
Phase 1Not yet taking people in China
A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy
Where
Qingdao
Age
18 years to 70 years
People
18
Run by
The Affiliated Hospital of Qingdao University
See details and how to joinNCT07676266
No phaseTaking people
Cohort Study on Neuroimmune Diseases in the Reproductive Age
Where
Guangzhou
Age
20 years to 55 years
People
100
Run by
Third Affiliated Hospital, Sun Yat-Sen University
See details and how to joinNCT07653984
No phaseNot yet taking people in China
A Study to Evaluate MTM-H-001 Injection in Adult Patients With B-Cell-Related Autoimmune Diseases
Where
Beijing
Age
18 years to 75 years
People
75
Run by
Beijing GoBroad Hospital
See details and how to joinNCT07593911
Early phase 1Taking people
CD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Diseases
Where
Wuhan
Age
18 years to 70 years
People
36
Run by
Tongji Hospital
See details and how to joinNCT07337785
Phase 1Taking people
Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.
Where
Wuhan
Age
18 years to 75 years
People
6
Run by
Tongji Hospital
See details and how to joinNCT07526493
Phase 3Taking people
A Study of Telitacicept in Patients With Ocular Myasthenia Gravis (OMG)
Where
Beijing
Age
12 years to 80 years
People
120
Run by
RemeGen Co., Ltd.
See details and how to joinNCT07249632
No phaseTaking people
Efficacy and Safety of HN2302 in Refractory Myasthenia Gravis(MG)
Where
Xuzhou
Age
18 years to 80 years
People
6
Run by
The Affiliated Hospital of Xuzhou Medical University
See details and how to joinNCT07413835
No phaseTaking people
Clinical Study of EVM18001 in the Treatment of Refractory Autoimmune Diseases
Where
Wuhan
Age
18 years to 70 years
People
12
Run by
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
See details and how to joinNCT07470151
No phaseNot yet taking people in China
A Study on the Efficacy and Safety of Telitacicept in the Treatment of Children Ocular Myasthenia Gravis
Where
Hangzhou, Jinan, Shenzhen
Age
Up to 18 years
People
30
Run by
The Children's Hospital of Zhejiang University School of Medicine
See details and how to joinNCT07298928
No phaseTaking people
Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs)
Where
Beijing, Changchun, Chengdu, Guangzhou, Jinan, Nanchang, Qingdao, Shijiazhuang
Age
18 years and over
People
500 worldwide
Run by
Alexion Pharmaceuticals, Inc.
See details and how to joinNCT04202341